Patient Disease:

Malignant Neoplasia

Study Name:

Single Dose Plasma Pharmacokinetic Analysis of Targeted Anticancer Agents in Tumor Bearing Dogs

Purpose of the study:

  • To measure blood levels of targeted therapy drugs over 96 hours following a single subcutaneous dose in dogs with cancer 

Primary Eligibility Criteria:

  • Weight at least 10 kg (22 lb) 
  • Confirmed diagnosis of cancer 
  • Adequate bloodwork parameters 
  • 7-day washout from any anti-cancer treatment 
  • Pets must come to CSU for all visits related to the clinical trial 

Study Protocol:

  • Dogs will receive a single subcutaneous dose of one of the drugs 
  • A small amount of drug will be collected at various timepoints over 24 hours 
  • Additional blood samples will be collected 48 and 96 hours after treatment 
  • After the 96-hour blood sample is drawn, the study is complete 

Owner Responsibilities:

  • Initial exam fee 
  • Diagnostics to confirm your dog’s cancer diagnosis 

Financial Incentives:

  • All costs related to the study 
  • $500 credit to VTH account upon study completion 
  • Funds are available to pay for the blood tests needed to determine study eligibility 

If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.